Is Shree Pacetronix overvalued or undervalued?

As of 18 November 2025, Shree Pacetronix's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 45.34, an EV to EBITDA ratio of 25.37, and a ROCE of 18.04%. In comparison to peers, Shree Pacetronix's PE ratio is significantly lower than Laxmi Dental's 62.73 and Poly Medicure's 53.17, but higher than Raaj Medisafe's 13.9, which is categorized as very attractive.
While Shree Pacetronix has demonstrated strong returns, with a year-to-date stock return of 114.84% compared to the Sensex's 8.36%, its valuation metrics suggest that it is currently aligned with market expectations. The PEG ratio of 0.00 indicates a lack of growth expectations priced into the stock, further supporting the fair valuation conclusion. Overall, Shree Pacetronix appears to be fairly valued in the current market landscape.